Hayfever Is Affecting More Than Your Nose

You know the physical symptoms well — the sneezing, the itching, the relentless runny nose. But there's another side to hayfever that rarely makes it onto a pollen forecast: the way it quietly chips away at your thinking, your sleep, and your emotional resilience. If you've ever found yourself struggling to focus at work during peak pollen season, lying awake at 3am with a congested nose, or feeling inexplicably low in summer, the research suggests you're not imagining it. And the medication you're reaching for to cope might be making some of it worse.

---

The Science

Your Brain on Pollen

The cognitive costs of hayfever are both real and surprisingly well-documented — though the picture is more nuanced than a simple cause-and-effect.

A systematic review by Vandenplas, Vinnikov, and Blanc (2017) confirmed that allergic rhinitis (AR) is associated with significant presenteeism — showing up to work while functioning below your best — as well as measurable absenteeism. What's interesting is why: proposed mechanisms centre on histamine and pro-inflammatory cytokines crossing into the central nervous system, disrupting the neural circuits that govern attention, processing speed, and working memory. In a controlled study, Wilken, Berkowitz, and Kane (2002) demonstrated measurable decrements in vigilance and cognitive functioning in participants exposed to ragweed allergen — with objective test scores dropping in ways that correlated with symptom severity.

Yet other controlled studies, including Kremer et al. (2002), found no significant objective impairment on neuropsychological testing. This contradiction is important and worth sitting with: it doesn't mean hayfever doesn't impair cognition — it likely means that standard short-term lab tests aren't sensitive enough to capture the real-world cost. One compelling explanation is the compensatory effort hypothesis: during a pollen spike, your brain works significantly harder to maintain the same output. You get through the meeting, you finish the report — but the cost is exhaustion, reduced cognitive reserve, and the cumulative productivity drain that plays out over days and weeks, not in a 45-minute lab session.

A MASK-air® study by Viera, Pham-Thi, and Anto (2022) found that young people with AR reported significantly lower academic productivity on high-symptom days, which maps onto the lived experience most hayfever sufferers will recognise: the season doesn't just make you sneeze, it makes sustained intellectual effort feel effortful in a way it normally isn't.

The Sleep Disruption Loop

Compounding the cognitive picture is one of hayfever's most underappreciated effects: what it does to your nights.

A 2020 systematic review and meta-analysis by Liu, Zhang, and Zhao confirmed across multiple observational studies that untreated AR is consistently associated with longer time to fall asleep, more frequent nocturnal awakenings, increased daytime sleepiness, and greater fatigue compared to people without AR. A landmark cross-sectional study by Léger, Annesi-Maesano, and Carat (2006) found that both the severity and the duration of AR symptoms directly correlated with the degree of sleep impairment.

The mechanism is intuitive once you know it: nasal congestion from IgE-mediated inflammation worsens when you're lying down, because gravity is no longer helping drain your nasal passages. This promotes mouth breathing, snoring, and in some cases sleep-disordered breathing with real apnea risk. Simultaneously, histamine released during allergic reactions directly promotes wakefulness through hypothalamic pathways — your own immune chemistry is keeping you alert when you want to be asleep. And the cytokines circulating during allergic flares further disrupt the sleep-wake regulation systems that govern how deeply and restoratively you sleep.

The result is a feedback loop: poor sleep reduces cognitive reserve, which makes the cognitive impairment from inflammation worse, which makes compensatory effort more exhausting, which further degrades sleep quality.

The Emotional Dimension

Perhaps the most striking — and least-discussed — finding in the AR research is its consistent association with depression and anxiety.

A 2021 systematic review and meta-analysis by Rodrigues, Franco-Pêgo, and Sousa-Pinto found that people with allergic rhinitis face approximately 1.4–1.9 times higher odds of anxiety and depression compared to those without AR. A 2024 umbrella review by Xu, Li, and Chen, encompassing tens of millions of individuals across multiple meta-analyses, corroborated these findings. Most strikingly, severe AR was associated with up to 2.7-fold greater depression risk compared to mild AR — suggesting a dose-response relationship, not just correlation.

The proposed mechanisms go beyond simply feeling miserable about your symptoms. Th2-skewed immune responses — the same immunological pattern that drives allergic disease — generate cytokines including IL-4, IL-5, and IL-13 that can influence neuroinflammation and mood regulation. HPA axis dysregulation and aeroallergen-timed depressive episodes have also been observed, suggesting a more direct immunological trigger. This is reinforced by the fact that temporal studies have found depressive episodes correlating with high-allergen exposure periods, independent of symptom burden alone.

The Medication Paradox

Here's the part that often surprises people: the medication most commonly used to manage hayfever may itself be contributing to cognitive and safety risks.

First-generation antihistamines — diphenhydramine, chlorphenamine, clemastine — remain widely available and commonly used. A comprehensive summary of on-road driving studies by O'Hanlon and Ramaekers (1995) and a subsequent review by Verster and Volkerts (2004) demonstrated that these medications produce driving impairment comparable to, or in some cases exceeding, a blood-alcohol concentration of 0.1% — well above the legal limit in most countries. A critical finding: users cannot reliably assess their own impairment. Subjective drowsiness does not predict actual performance deficits, meaning people feel fine to drive when objective measures say they aren't.

The mechanism is the lipophilicity of first-generation agents — they readily cross the blood-brain barrier, where they antagonise central H1 receptors, slowing reaction time and impairing psychomotor coordination. Second-generation antihistamines such as fexofenadine and loratadine are engineered with lower CNS penetrance and show driving performance comparable to placebo in most studies. Cetirizine occupies a middle ground and may impair a subset of sensitive individuals.

---

What This Means for You

If you've been treating hayfever as a seasonal inconvenience — something to push through — this body of evidence reframes it as a condition with genuine systemic consequences. Not catastrophic ones, but real, cumulative, and largely preventable ones.

The cognitive fog, the low mood in summer, the exhaustion that doesn't seem proportional to how busy you've been — these aren't character flaws or stress responses. For many hayfever sufferers, they're biological consequences of sustained allergic inflammation combined, in some cases, with medication that adds its own sedative burden.

The good news is that most of this is modifiable. The sleep disruption from nasal congestion responds well to treatment: a 2024 systematic review and meta-analysis by Tabata, Sumi, and Sasaki confirmed that intranasal corticosteroids significantly improve sleep disturbances in AR patients. Switching from sedating to non-sedating antihistamines removes a preventable impairment risk. And pollen-personalised timing of treatment — getting ahead of your peak exposure rather than reacting to it — can reduce the inflammatory load that drives both cognitive and emotional consequences.

---

The Evidence Landscape

It's important to be honest about what the science doesn't yet fully resolve. The relationship between AR and depression/anxiety is robustly documented in association studies, but causal directionality remains unproven — shared inflammatory, genetic, or socioeconomic pathways may partly explain the link. We don't yet have randomised trial data showing that effectively treating AR reduces depression or anxiety risk, which is a meaningful gap.

On the cognitive side, the disconnect between subjective impairment complaints and objective test performance is a genuine puzzle. The compensatory effort hypothesis is plausible and fits the data well, but hasn't been definitively tested with the kind of longitudinal, real-world productivity measures that would resolve it. The field needs studies that combine objective output metrics, inflammation biomarkers, and pollen-personalised exposure timing — something that's logistically complex but scientifically necessary.

What we can say with confidence: the sleep impairment evidence is solid, the driving impairment evidence for first-generation antihistamines is strong and well-replicated, and the association between AR and mood disorders is consistent across large populations. These are not marginal effects.

---

What Haelo Recommends

1. Don't wait for symptoms to peak before treating. The cognitive and sleep costs of allergic inflammation are cumulative. Pre-emptive treatment — started a week or two before your personal pollen peak — reduces the inflammatory load before it builds. Haelo's pollen intelligence can help you identify when that window is.

2. Know what's in your antihistamine. If you're taking a sedating (first-generation) antihistamine, treat driving and complex work tasks the same way you'd treat a post-alcohol situation. Better still, discuss switching to a non-sedating alternative like fexofenadine or loratadine with your pharmacist or GP — particularly if you're in a period of high pollen exposure and demanding work.

3. Take your sleep seriously as part of AR management. Nasal congestion at night is treatable. Intranasal corticosteroids are evidence-supported for improving AR-related sleep disturbances — and improving your sleep will cascade positively into cognitive function and mood. Elevation of the head of your bed and nasal saline irrigation before sleep can also help reduce nocturnal congestion.

4. If you're feeling low or anxious during pollen season, consider the biological component. This isn't to say hayfever causes depression — the evidence isn't there for a clean causal claim. But if your mood reliably dips during high-pollen periods, that's clinically relevant information worth discussing with a doctor. It's not just in your head — or rather, it is, but in a biochemical sense that warrants attention.

5. Track your own patterns. The most important data is yours. Logging symptoms, sleep quality, mood, and cognitive function alongside pollen levels over a season creates a personalised picture that population-level research simply can't provide. Haelo is built to help you do exactly this.

---

The science on hayfever's wider impacts on wellbeing is still developing, and Haelo will continue to update its guidance as the evidence grows. Where uncertainty exists, we'll always tell you.